|
1
|
Anderson BO, Shyyan R, Eniu A, Smith RA,
Yip CH, Bese NS, Chow LW, Masood S, Ramsey SD and Carlson RW:
Breast cancer in limited-resource countries: An overview of the
breast health global initiative 2005 guidelines. Breast J. 12 Suppl
1:S3–S15. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Peng C, Ma W, Xia W and Zheng W:
Integrated analysis of differentially expressed genes and pathways
in triple-negative breast cancer. Mol Med Rep. 15:1087–1094. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gupta A, Godwin AK, Vanderveer L, Lu A and
Liu J: Hypomethylation of the synuclein gamma gene CpG island
promotes its aberrant expression in breast carcinoma and ovarian
carcinoma. Cancer Res. 63:664–673. 2003.PubMed/NCBI
|
|
4
|
Inaba S, Li C, Shi YE, Song DQ, Jiang JD
and Liu J: Synuclein gamma inhibits the mitotic checkpoint function
and promotes chromosomal instability of breast cancer cells. Breast
Cancer Res Treat. 94:25–35. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gupta A, Inaba S, Wong OK, Fang G and Liu
J: Breast cancer-specific gene 1 interacts with the mitotic
checkpoint kinase BubR1. Oncogene. 22:7593–7599. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pan ZZ, Bruening W, Giasson BI, Lee VM and
Godwin AK: Gamma-synuclein promotes cancer cell survival and
inhibits stress and chemotherapy drug-induced apoptosis by
modulating MAPK pathways. J Biol Chem. 277:35050–35060. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Howard EM, Lau SK, Lyles RH, Birdsong GG,
Tadros TS, Umbreit JN and Kochhar R: Correlation and expression of
p53, HER-2, vascular endothelial growth factor (VEGF), and
e-cadherin in a high-risk breast-cancer population. Int J Clin
Oncol. 9:154–160. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Singh VK, Zhou Y, Marsh JA, Uversky VN,
Forman-kay JD, Liu J and Jia Z: Synuclein-gamma targeting peptide
inhibitor that enhances sensitivity of breast cancer cells to
antimicrotubule drugs. Cancer Res. 67:626–633. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Arriagada R, Le Chevalier T, Pignon JP,
Rivière A, Monnet I, Chomy P, Tuchais C, Tarayre M and Ruffié P:
Initial chemotherapeutic doses and survival in patients with
limited small-cell lung cancer. N Engl J Med. 329:1848–1852. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kester M, Heakal Y, Fox T, Sharma A,
Robertson GP, Morgan TT, Altinoğlu EI, Tabaković A, Parette MR,
Rouse SM, et al: Calcium phosphate nanocomposite particles for in
vitro imaging and encapsulated chemotherapeutic drug delivery to
cancer cells. Nano Lett. 8:4116–4121. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cichewicz RH and Kouzi SA: Chemistry,
biological activity, and chemotherapeutic potential of betulinic
acid for the prevention and treatment of cancer and HIV infection.
Med Res Rev. 24:90–114. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shree T, Olson OC, Elie BT, Kester JC,
Garfall AL, Simpson K, Bell-McGuinn KM, Zabor EC, Brogi E and Joyce
JA: Macrophages and cathepsin proteases blunt chemotherapeutic
response in breast cancer. Genes Dev. 25:2465–2479. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Davis ME, Zuckerman JE, Choi CH, Seligson
D, Tolcher A, Alabi CA, Yen Y, Heidel JD and Ribas A: Evidence of
RNAi in humans from systemically administered siRNA via targeted
nanoparticles. Nature. 464:1067–1070. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Han HD, Mangala LS, Lee JW, Shahzad MM,
Kim HS, Shen D, Nam EJ, Mora EM, Stone RL, Lu C, et al: Targeted
gene silencing using RGD-labeled chitosan nanoparticles. Clin
Cancer Res. 16:3910–3922. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Varshosaz J and Taymouri S: Hollow
inorganic nanoparticles as efficient carriers for siRNA delivery: A
comprehensive review. Curr Pharm Des. 21:4310–4328. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen SJ, Zhang HZ, Wan LC, Jiang SS, Xu
YM, Liu F, Zhang T, Ma D and Xie MQ: Preparation and performance of
a pH-sensitive cisplatin-loaded magnetic nanomedicine that targets
tumor cells via folate receptor mediation. Mol Med Rep.
13:5059–5067. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim DH, Villeneuve LM, Morris KV and Rossi
JJ: Argonaute-1 directs siRNA-mediated transcriptional gene
silencing in human cells. Nat Struct Mol Biol. 13:793–797. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Judge AD, Sood V, Shaw JR, Fang D,
McClintock K and MacLachlan I: Sequence-dependent stimulation of
the mammalian innate immune response by synthetic siRNA. Nat
Biotechnol. 23:457–462. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pillé JY, Li H, Blot E, Bertrand JR,
Pritchard LL, Opolon P, Maksimenko A, Lu H, Vannier JP, Soria J, et
al: Intravenous delivery of anti-RhoA small interfering RNA loaded
in nanoparticles of chitosan in mice: Safety and efficacy in
xenografted aggressive breast cancer. Hum Gene Ther. 17:1019–1026.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu Y and Du Y: Effect of molecular
structure of chitosan on protein delivery properties of chitosan
nanoparticles. Int J Pharm. 250:215–226. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yin L, Ding J, He C, Cui L, Tang C and Yin
C: Drug permeability and mucoadhesion properties of thiolated
trimethyl chitosan nanoparticles in oral insulin delivery.
Biomaterials. 30:5691–5700. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shi Z, Neoh KG, Kang ET and Wang W:
Antibacterial and mechanical properties of bone cement impregnated
with chitosan nanoparticles. Biomaterials. 27:2440–2449. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim JH, Kim YS, Park K, Lee S, Nam HY, Min
KH, Jo HG, Park JH, Choi K, Jeong SY, et al: Antitumor efficacy of
cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing
mice. J Control Release. 127:41–49. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Janes KA, Fresneau MP, Marazuela A, Fabra
A and Alonso MJ: Chitosan nanoparticles as delivery systems for
doxorubicin. J Control Release. 73:255–267. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hwang HY, Kim IS, Kwon IC and Kim YH:
Tumor targetability and antitumor effect of docetaxel-loaded
hydrophobically modified glycol chitosan nanoparticles. J Control
Release. 128:23–31. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu Y, Yang W, Wang C, Hu J and Fu S:
Chitosan nanoparticles as a novel delivery system for ammonium
glycyrrhizinate. Int J Pharm. 295:235–245. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim JH, Kim YS, Park K, Kang E, Lee S, Nam
HY, Kim K, Park JH, Chi DY, Park RW, et al: Self-assembled glycol
chitosan nanoparticles for the sustained and prolonged delivery of
antiangiogenic small peptide drugs in cancer therapy. Biomaterials.
29:1920–1930. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
He L, Huang Y, Zhu H, Pang G, Zheng W,
Wong YS and Chen T: Cancer-targeted monodisperse mesoporous silica
nanoparticles as carrier of ruthenium polypyridyl complexes to
enhance theranostic effects. Adv Func Mat. 24:2754–2763. 2014.
View Article : Google Scholar
|
|
29
|
Zhang Q, Liu F, Nguyen KT, Ma X, Wang X,
Xing B and Zhao Y: Multifunctional mesoporous silica nanoparticles
for cancer-targeted and controlled drug delivery. Adv Func Mat.
22:5144–5156. 2012. View Article : Google Scholar
|
|
30
|
Cai LL, Liu P, Li X, Huang X, Ye YQ, Chen
FY, Yuan H, Hu FQ and Du YZ: RGD peptide-mediated chitosan-based
polymeric micelles targeting delivery for integrin-overexpressing
tumor cells. Int J Nanomedicine. 6:3499–3508. 2011.PubMed/NCBI
|
|
31
|
Mansur AA, de Carvalho SM and Mansur HS:
Bioengineered quantum dot/chitosan-tripeptide nanoconjugates for
targeting the receptors of cancer cells. Int J Biol Macromol.
82:780–789. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu TY, Chen SY, Lin YL and Liu DM:
Synthesis and characterization of amphiphatic
carboxymethyl-hexanoyl chitosan hydrogel: Water-retention ability
and drug encapsulation. Langmuir. 22:9740–9745. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu KH, Chen SY, Liu DM and Liu TY:
Self-assembled hollow nanocapsule from amphiphatic
carboxymethyl-hexanoyl chitosan as drug carrier. Macromolecules.
41:6511–6516. 2008. View Article : Google Scholar
|
|
34
|
Burdick JA and Anseth KS:
Photoencapsulation of osteoblasts in injectable RGD-modified PEG
hydrogels for bone tissue engineering. Biomaterials. 23:4315–4323.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li WM, Liu DM and Chen SY:
Amphiphilically-modified gelatin nanoparticles: Self-assembly
behavior, controlled biodegradability, and rapid cellular uptake
for intracellular drug delivery. J Mat Chem. 21:12381–12388. 2011.
View Article : Google Scholar
|
|
36
|
Reynolds AR, Hart IR, Watson AR, Welti JC,
Silva RG, Robinson SD, Da Violante G, Gourlaouen M, Salih M, Jones
MC, et al: Stimulation of tumor growth and angiogenesis by low
concentrations of RGD-mimetic integrin inhibitors. Nat Med.
15:392–400. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Krajewska M, Krajewski S, Epstein JI,
Shabaik A, Sauvageot J, Song K, Kitada S and Reed JC:
Immunohistochemical analysis of bcl-2, bax, bcl-X and mcl-1
expression in prostate cancer. Am J Pathol. 148:1567–1576.
1996.PubMed/NCBI
|
|
38
|
Dastjerdi MN, Rarani MZ, Valiani A and
Mahmoudieh M: The effect of adenosine A1 receptor agonist and
antagonist on p53 and caspase 3, 8, and 9 expression and apoptosis
rate in MCF-7 breast cancer cell line. Res Pharm Sci. 11:303–310.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wu BB, Gong YP, Wu XH, Chen YY, Chen FF,
Jin LT, Cheng BR, Hu F and Xiong B: Fourier transform infrared
spectroscopy for the distinction of MCF-7 cells treated with
different concentrations of 5-fluorouracil. J Transl Med.
13:1082015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
França EL, Honorio-frança AC, Fernandes
RT, Marins CM, Pereira CC and Fde Varotti P: The effect of
melatonin adsorbed to polyethylene glycol microspheres on the
survival of MCF-7 cells. Neuroimmunomodulation. 23:27–32. 2016.
View Article : Google Scholar : PubMed/NCBI
|
